|
GB0108591D0
(en)
|
2001-04-05 |
2001-05-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0120347D0
(en)
|
2001-08-21 |
2001-10-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
EP1453516A2
(de)
*
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
|
RU2304140C2
(ru)
|
2001-12-27 |
2007-08-10 |
Дайити Фармасьютикал Ко., Лтд. |
ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА
|
|
GB0223039D0
(en)
*
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
|
RU2336270C2
(ru)
|
2003-06-30 |
2008-10-20 |
Дайити Фармасьютикал Ко., Лтд. |
Гетероциклические метилсульфоновые производные
|
|
GB0323258D0
(en)
*
|
2003-10-04 |
2003-11-05 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
JP2008503460A
(ja)
*
|
2004-06-16 |
2008-02-07 |
ワイス |
β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
|
|
EP2264036A1
(en)
*
|
2005-01-14 |
2010-12-22 |
Wyeth LLC (Formerly Known As Wyeth) |
Amino-imidazolones for the inhibition of beta-secretase
|
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
|
EP1888051A2
(en)
*
|
2005-05-17 |
2008-02-20 |
MERCK SHARP & DOHME LTD. |
Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
|
|
GB0513747D0
(en)
*
|
2005-07-06 |
2005-08-10 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
US8133857B2
(en)
|
2006-03-07 |
2012-03-13 |
The Brigham and Women's FHospital, Inc. |
NOTCH inhibition in the treatment of atherosclerosis
|
|
US9567396B2
(en)
|
2006-03-07 |
2017-02-14 |
Evonik Degussa Gmbh |
Notch inhibition in the prevention of vein graft failure
|
|
WO2011053822A2
(en)
|
2009-11-01 |
2011-05-05 |
The Brigham And Women's Hospital, Inc. |
Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
|
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
|
|
EP2094836B1
(en)
|
2006-11-15 |
2016-06-08 |
Massachusetts Eye & Ear Infirmary |
Generation of inner ear cells
|
|
EP2091948B1
(en)
|
2006-11-30 |
2012-04-18 |
Probiodrug AG |
Novel inhibitors of glutaminyl cyclase
|
|
AU2008215948A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
CA2679446C
(en)
|
2007-03-01 |
2016-05-17 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
US8377886B2
(en)
*
|
2007-09-14 |
2013-02-19 |
Albert Einstein College Of Medicine Of Yeshiva University |
Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
|
|
US8461389B2
(en)
|
2008-04-18 |
2013-06-11 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
AU2009239555A1
(en)
*
|
2008-04-23 |
2009-10-29 |
Merck Sharp & Dohme Corp. |
Cyclobutyl sulfones as Notch sparing gamma secretase inhibitors
|
|
CA2743436C
(en)
|
2008-11-24 |
2017-10-31 |
Massachusetts Eye & Ear Infirmary |
Pathways to generate hair cells
|
|
US8609897B2
(en)
|
2009-02-06 |
2013-12-17 |
Merck Sharp & Dohme Corp. |
Trifluoromethylsulfonamide gamma secretase inhibitor
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
WO2011009064A1
(en)
*
|
2009-07-17 |
2011-01-20 |
The J. David Gladstone Institutes |
Methods of controlling cell proliferation
|
|
BR112012008346B1
(pt)
|
2009-09-11 |
2021-12-21 |
Vivoryon Therapeutics N.V. |
Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
|
|
EP2477963A4
(en)
*
|
2009-09-18 |
2013-02-27 |
Zalicus Pharmaceuticals Ltd |
ARYLSULFON DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
|
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
DK2545047T3
(da)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
|
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
|
|
JP2013537423A
(ja)
|
2010-08-17 |
2013-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
|
WO2013059302A1
(en)
|
2011-10-17 |
2013-04-25 |
Nationwide Children's Hospital, Inc. |
Products and methods for aortic abdominal aneurysm
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
JP6486272B2
(ja)
|
2012-09-07 |
2019-03-20 |
マサチューセッツ・アイ・アンド・イア・インファーマリー |
有毛細胞および／または支持細胞再生のための方法および組成物
|
|
HK1211875A1
(en)
|
2012-09-07 |
2016-06-03 |
Massachusetts Eye & Ear Infirmary |
Treating hearing loss
|
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
|
RS56680B1
(sr)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme |
Kompozicije i postupci za lečenje kancera
|
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
US8859286B2
(en)
|
2013-03-14 |
2014-10-14 |
Viacyte, Inc. |
In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015104343A1
(en)
*
|
2014-01-09 |
2015-07-16 |
Proyecto De Biomedicina Cima, S.L. |
New antifibrinolytic compounds
|
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
|
WO2016022776A2
(en)
|
2014-08-06 |
2016-02-11 |
Massachusetts Eye And Ear Infirmary |
Increasing atoh1 life to drive sensorineural hair cell differentiantion
|
|
SG10201913841SA
(en)
|
2015-07-24 |
2020-03-30 |
Oncotracker Inc |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
US11185536B2
(en)
|
2015-12-04 |
2021-11-30 |
Massachusetts Eye And Ear Infirmary |
Treatment of hearing loss by inhibition of casein kinase 1
|
|
CN109219439B
(zh)
|
2016-01-29 |
2022-09-20 |
马萨诸塞眼科耳科诊所 |
内耳支持细胞的扩增和分化及其使用方法
|
|
CA3024424A1
(en)
|
2016-05-16 |
2017-11-23 |
The General Hospital Corporation |
Human airway stem cells in lung epithelial engineering
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
JP6904612B2
(ja)
|
2016-12-16 |
2021-07-21 |
パイプライン セラピューティクス， インコーポレイテッド |
蝸牛シナプス障害を処置する方法
|
|
CN110461335A
(zh)
|
2017-02-17 |
2019-11-15 |
弗雷德哈钦森癌症研究中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CA3108388A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2020033285A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2021126728A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
JP7589247B2
(ja)
|
2019-12-17 |
2024-11-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｐｒｍｔ５阻害剤
|
|
EP4076460B1
(en)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
|
|
WO2021195362A1
(en)
|
2020-03-26 |
2021-09-30 |
Seagen Inc. |
Methods of treating multiple myeloma
|
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
GEAP202516720A
(en)
|
2022-09-02 |
2025-07-10 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
IL320396A
(en)
|
2022-10-25 |
2025-06-01 |
Merck Sharp & Dohme Llc |
Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
|
|
US20240207425A1
(en)
|
2022-12-14 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|